Pharvaris achieves primary goal in late-stage trial of deucrictibant for HAE
Source: SeekingAlpha
2025-12-03 10:40:53 ET
More on Pharvaris
- Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating
- Pharvaris N.V. (PHVS) Presents at ACAAI 2025 Annual Scientific Meeting - Slideshow
- Pharvaris N.V. (PHVS) Presents at 2025 HAE International (HAEi) Regional Conference EMEA - Slideshow
- Pharvaris GAAP EPS of -€0.60
- Seeking Alpha’s Quant Rating on Pharvaris
Read the full article on Seeking Alpha
For further details see:
Pharvaris achieves primary goal in late-stage trial of deucrictibant for HAE
Pharvaris N.V.
NASDAQ: PHVS
PHVS Trading
3.09% G/L:
$26.36 Last:
56,569 Volume:
$26.12 Open:
PHVS Latest News
PHVS Stock Data
$1,492,567,159
37,790,994
N/A
37
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
